LLY · 10-Q · 2026Q2 · Full report

Manufacturing Capacity

ELI LILLY & Co · 2026-08-05 · Importance 37 · Surprise 42

Lilly is making investments in global facilities to manufacture existing and future products. These investments have increased capital expenditures and are expected to produce meaningfully higher capital expenditures in the near term. Additional manufacturing capacity is expected to become operational over the next several years. The expansion is intended to support anticipated demand for Mounjaro, Zepbound, Foundayo, and other current and prospective incretin products.

Key facts

• The Company expects additional manufacturing capacity to become operational over the next several years to support anticipated demand. source